Literature DB >> 9755706

High-resolution MR imaging of the cutis and subcutis. Histological correlation.

B Krug1, H Kugel, H J Schulze, T Krahe, J Gieseke, K Lackner.   

Abstract

OBJECTIVE: To determine whether the spatial resolution that can be achieved with currently available MR devices is adequate for the evaluation of skin disease.
MATERIAL AND METHODS: We correlated high-resolution MR images of the skin with dermatohistopathology in 26 patients. The examinations were carried out on a 1.0 T imager using a commercially available surface coil (ID 7.5 cm) and optimized SE and GE sequences. Image quality was assessed by four readers on a questionnaire.
RESULTS: The visualization of the dermis, subcutaneous tissue, and muscle fascia allowed a pattern analysis that gave findings identical to those at dermatohistopathology. It was possible to distinguish septal from lobular panniculitis, and lipatrophia from sclerodermia. Images with contrast media infusion were useful in the differential diagnosis.
CONCLUSION: High-resolution MR imaging may narrow down the differential diagnosis of various skin diseases and may help to reduce the number of skin biopsies on certain indications.

Entities:  

Mesh:

Year:  1998        PMID: 9755706     DOI: 10.1080/02841859809172223

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  2 in total

1.  Sarcoidosis with high serum levels of vascular endothelial growth factor (VEGF), showing RS3PE-like symptoms in extremities.

Authors:  Masayuki Matsuda; Kumi Sakurai; Tomohisa Fushimi; Kanji Yamamoto; Shiho Rokuhara; Naritoshi Hosaka; Shu-ichi Ikeda
Journal:  Clin Rheumatol       Date:  2004-02-11       Impact factor: 2.980

2.  Accuracy of preoperative MRI with microscopy coil in evaluation of primary tumor thickness of malignant melanoma of the skin with histopathologic correlation.

Authors:  Yusuhn Kang; Jung-Ah Choi; Jin-Haeng Chung; Sung Hwan Hong; Heung Sik Kang
Journal:  Korean J Radiol       Date:  2013-02-22       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.